Literature DB >> 12499468

Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy.

Georg Lemm1.   

Abstract

The use of intravenous immune globulin (IVIg) has increased significantly in the past decade, benefiting a wide variety of immune diseases. Seven different formulations of IVIg are now licensed in the United States. Although all contain pooled IgG, there are differences in their production and composition that affect their efficacy, tolerability, and side-effect profile. Important variables include concentration, volume, osmolality, sodium, and sugar content. This article reviews what is known about the composition and properties of the various IVIg formulations that might affect the therapeutic outcome.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12499468     DOI： 10.1212/wnl.59.12_suppl_6.s28

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  7 in total

Review 1.  Renal transplantation in high-risk patients.

Authors:  Nicole A Weimert; Rita R Alloway
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study.

Authors:  Frances Rose R Palabrica; Shirley L Kwong; Florecita R Padua
Journal:  Asia Pac Allergy       Date:  2013-10-31

3.  Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.

Authors:  Daniel Suez; Mark Stein; Sudhir Gupta; Iftikhar Hussain; Isaac Melamed; Kenneth Paris; Amy Darter; Christelle Bourgeois; Sandor Fritsch; Heinz Leibl; Barbara McCoy; David Gelmont; Leman Yel
Journal:  J Clin Immunol       Date:  2016-08-31       Impact factor: 8.317

Review 4.  Adverse Effects of Immunoglobulin Therapy.

Authors:  Yi Guo; Xin Tian; Xuefeng Wang; Zheng Xiao
Journal:  Front Immunol       Date:  2018-06-08       Impact factor: 7.561

5.  Predictive factors of first dosage intravenous immunoglobulin-related adverse effects in children.

Authors:  Jun Kubota; Shin-Ichiro Hamano; Atsuro Daida; Erika Hiwatari; Satoru Ikemoto; Yuko Hirata; Ryuki Matsuura; Daishi Hirano
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

6.  Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity.

Authors:  Josephine H Cheng; Yu-Wen Wu; Chen-Yun Wang; Sharon S Wu; Cheum L Hong; Karen W Chan; Leo X Liao; Xisheng Cao; Bin Wang; Thierry Burnouf
Journal:  Blood Transfus       Date:  2021-08-04       Impact factor: 3.443

7.  Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.

Authors:  M Borte; G Kriván; B Derfalvi; L Maródi; T Harrer; S Jolles; C Bourgeois; W Engl; H Leibl; B McCoy; D Gelmont; L Yel
Journal:  Clin Exp Immunol       Date:  2016-10-18       Impact factor: 4.330
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.